Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Deconinck

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
The Lancet. Neurology|October 16, 2022
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trialRiccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose, et al.
Plos One|April 11, 2015
Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trialAndreea Mihaela Seferian, Amélie Moraux, Aurélie Canal, et al.
Neuromuscular Disorders : NMD|January 29, 2025
Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B)Bettina C Henzi, Niveditha Putananickal, Simone Schmidt, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trialEugenio Mercuri, Nicolas Deconinck, Elena S Mazzone, et al.
Pediatric Neurology|July 4, 2024
Congenital Myasthenic Syndromes in Belgium: Genetic and Clinical Characterization of Pediatric and Adult PatientsNathalie Smeets, Alexander Gheldof, Bart Dequeker, et al.
Annals of Neurology|December 4, 2019
ASC-1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of MyopathyRocío N Villar-Quiles, Fabio Catervi, Eva Cabet, et al.
Neuromuscular Disorders : NMD|February 15, 2026
Safety and efficacy of tamoxifen in patients with duchenne muscular dystrophy: open label extension of TAMDMD trialGaëtan Zwingli, Niveditha Putananickal, Simone Schmidt, et al.
Scientific Reports|October 8, 2021
Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern BelgiumFrançois Boemer, Jean-Hubert Caberg, Pablo Beckers, et al.
Plos One|February 3, 2015
Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trialAndreea Mihaela Seferian, Amélie Moraux, Mélanie Annoussamy, et al.
Genome Medicine|July 21, 2017
Novel promoters and coding first exons in DLG2 linked to developmental disorders and intellectual disabilityClaudio Reggiani, Sandra Coppens, Tayeb Sekhara, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
The Lancet. Neurology|October 16, 2022
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trialRiccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose, et al.
Plos One|April 11, 2015
Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trialAndreea Mihaela Seferian, Amélie Moraux, Aurélie Canal, et al.
Neuromuscular Disorders : NMD|January 29, 2025
Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B)Bettina C Henzi, Niveditha Putananickal, Simone Schmidt, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trialEugenio Mercuri, Nicolas Deconinck, Elena S Mazzone, et al.
Pediatric Neurology|July 4, 2024
Congenital Myasthenic Syndromes in Belgium: Genetic and Clinical Characterization of Pediatric and Adult PatientsNathalie Smeets, Alexander Gheldof, Bart Dequeker, et al.
Annals of Neurology|December 4, 2019
ASC-1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of MyopathyRocío N Villar-Quiles, Fabio Catervi, Eva Cabet, et al.
Neuromuscular Disorders : NMD|February 15, 2026
Safety and efficacy of tamoxifen in patients with duchenne muscular dystrophy: open label extension of TAMDMD trialGaëtan Zwingli, Niveditha Putananickal, Simone Schmidt, et al.
Scientific Reports|October 8, 2021
Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern BelgiumFrançois Boemer, Jean-Hubert Caberg, Pablo Beckers, et al.
Plos One|February 3, 2015
Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trialAndreea Mihaela Seferian, Amélie Moraux, Mélanie Annoussamy, et al.
Genome Medicine|July 21, 2017
Novel promoters and coding first exons in DLG2 linked to developmental disorders and intellectual disabilityClaudio Reggiani, Sandra Coppens, Tayeb Sekhara, et al.
Pageof 8